Shandong Xinhua Pharmaceutical Company Limited(000756),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

000756 Shandong Xinhua Pharmaceutical Company Limited

Trading 12-23 13:06:00

15.76

-0.08

-0.51%

High15.86	Low15.66	Vol7.20M
Open15.79	D1 Closing15.84	Amplitude1.26%
Mkt Cap10.87B	Tradable Cap7.77B	Total Shares690.00M
T/O113.00M	T/O Rate1.46%	Tradable Shares493.00M
P/B2.12	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"000756","market":"SZ","secType":"STK","nameCN":"Shandong Xinhua Pharmaceutical Company Limited","latestPrice":15.76,"timestamp":1766466360000,"preClose":15.84,"halted":0,"volume":7196391,"delay":0,"changeRate":-0.0051,"floatShares":493000000,"shares":690000000,"eps":0.5541,"marketStatus":"Trading","change":-0.08,"latestTime":"12-23 13:06:00","open":15.79,"high":15.86,"low":15.66,"amount":113000000,"amplitude":0.0126,"askPrice":15.77,"askSize":149,"bidPrice":15.76,"bidSize":158,"shortable":0,"etf":0,"ttmEps":0.5541,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766473200000},"marketStatusCode":2,"adr":0,"adjPreClose":15.84,"symbolType":"stock","openAndCloseTimeList":[[1766453400000,1766460600000],[1766466000000,1766473200000]],"highLimit":17.42,"lowLimit":14.26,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":689776535,"isCdr":false,"pbRate":2.12,"roa":"--","peRate":28.442519,"roe":"5.01%","epsLYR":0.69,"committee":0.371578,"marketValue":10871000000,"turnoverRate":0.0146,"status":1,"hkstockBrief":{"symbol":"00719","market":"HK","secType":"STK","nameCN":"SHANDONG XINHUA","latestPrice":6.72,"timestamp":1766466006768,"preClose":6.76,"halted":0,"volume":800000,"delay":0,"premium":"-61.52"},"floatMarketCap":7764000000},"requestUrl":"/m/hq/s/000756/tweets","defaultTab":"tweets","newsList":[{"id":"2586247367","title":"Xinhua Pharmaceutical Gets China Nod for Inflammatory Disease Drug-Related Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2586247367","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586247367?lang=en_us&edition=fundamental","pubTime":"2025-11-27 19:58","pubTimestamp":1764244726,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical  obtained marketing approval for the chemical active pharmaceutical ingredients related to Prednisolone Acetate from China's National Medical Products Administration, a Thursday Hong Kong bourse filing said.The drug is mainly used to treat allergic and autoimmune inflammatory diseases.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","BK1191","BK0164","00719","000756","BK0239"],"gpt_icon":0},{"id":"2586364247","title":"Xinhua Pharmaceutical's Dyspnea Drug Passes Chinese Regulator's Consistency Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2586364247","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586364247?lang=en_us&edition=fundamental","pubTime":"2025-11-27 19:58","pubTimestamp":1764244705,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical  said its Epinephrine Hydrochloride Injection passed China's National Medical Products Administration's consistency of quality and efficacy evaluation, a Thursday Hong Kong bourse filing said.The drug is mainly suitable for treating severe dyspnea caused by bronchospasm, can quickly relieve anaphylactic shock caused by medication, and can be used to prolong the action time of infiltration anesthesia.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","000756","BK0239","BK1515","00719","BK0164"],"gpt_icon":0},{"id":"1177726268","title":"Shandong Xinhua Pharmaceutical (000756.SZ): Adrenaline Hydrochloride Injection Passes Consistency Evaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=1177726268","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177726268?lang=en_us&edition=fundamental","pubTime":"2025-11-27 16:50","pubTimestamp":1764233425,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical Company Limited (000756.SZ) announced that it has received the \"Drug Supplement Approval Notice\" for its Adrenaline Hydrochloride Injection from the National Medical...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000756","BK0239","BK0164"],"gpt_icon":0},{"id":"2586724865","title":"Shandong Xinhua Pharmaceutical-  Prednisolone Acetate Got Approval of Marketing Application From China's Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2586724865","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586724865?lang=en_us&edition=fundamental","pubTime":"2025-11-27 16:34","pubTimestamp":1764232494,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251127:nFWN3X301J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["000756","BK0164","BK0239"],"gpt_icon":0},{"id":"2586248685","title":"Shandong Xinhua Pharmaceutical Co Ltd -  Approval From Nmpa of Epinephrine Hydrochloride Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2586248685","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586248685?lang=en_us&edition=fundamental","pubTime":"2025-11-27 16:33","pubTimestamp":1764232394,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251127:nFWN3X212C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2586248633","title":"Shandong Xinhua Pharmaceutical Wins China Approval for Prednisolone Acetate API","url":"https://stock-news.laohu8.com/highlight/detail?id=2586248633","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586248633?lang=en_us&edition=fundamental","pubTime":"2025-11-27 16:33","pubTimestamp":1764232386,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical Company Limited has announced that it has received the Notification of Approval of Marketing Application for Chemical Active Pharmaceutical Ingredients from the National Medical Products Administration for its product, Prednisolone Acetate. This approval is expected to further enrich the company's hormone product line and enhance its core competitiveness. The announcement notes that the pharmaceutical sales business remains susceptible to changes in industry policies and market environment, advising investors to exercise caution. There is no indication that the grant or approval was obtained by any organizations other than Shandong Xinhua Pharmaceutical Company Limited.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or le","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251127:nNDL54lq6Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2586365424","title":"Xinhua Pharmaceutical Obtains Registration Certificate for Local Skin Anesthesia Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2586365424","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586365424?lang=en_us&edition=fundamental","pubTime":"2025-11-25 18:46","pubTimestamp":1764067603,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical  received the drug registration certificate for its Lidocaine and Prilocaine Cream from China's National Medical Products Administration, a Tuesday Hong Kong bourse filing said.The cream is used for local skin anesthesia for needle puncture and superficial surgical operations.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","BK0239","BK1191","000756","BK0164","00719"],"gpt_icon":0},{"id":"1115836692","title":"Shandong Xinhua Pharmaceutical (000756.SZ) Obtains Drug Registration Certificate for Lidocaine and Prilocaine Cream","url":"https://stock-news.laohu8.com/highlight/detail?id=1115836692","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115836692?lang=en_us&edition=fundamental","pubTime":"2025-11-25 17:08","pubTimestamp":1764061719,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical Company Limited (000756.SZ) announced that it has received the Drug Registration Certificate for Lidocaine and Prilocaine Cream issued by the National Medical Products...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2586428920","title":"Shandong Xinhua Pharmaceutical Receives Drug Registration Certificate for Lidocaine and Prilocaine Cream","url":"https://stock-news.laohu8.com/highlight/detail?id=2586428920","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586428920?lang=en_us&edition=fundamental","pubTime":"2025-11-25 16:37","pubTimestamp":1764059878,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical Company Limited has announced that it has received a Drug Registration Certificate for its Lidocaine and Prilocaine Cream from Chinese regulatory authorities. The approval follows the company's application submission in February 2024 to the Center for Drug Evaluation of the State Drug Administration. This regulatory milestone is expected to enhance Xinhua Pharmaceutical's product portfolio and competitiveness in the pharmaceutical market. No other organizations were noted as recipients of this regulatory approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Xinhua Pharmaceutical Company Ltd. published the original content used to generate this news brief via via IIS, the Issuer Information Ser","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL2FzxtB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2586428915","title":"Shandong Xinhua Pharmaceutical -  Lidocaine and Prilocaine Cream Obtained Drug Registration Certificate From China's Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2586428915","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586428915?lang=en_us&edition=fundamental","pubTime":"2025-11-25 16:37","pubTimestamp":1764059873,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nFWN3X00SZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","BK0164","000756"],"gpt_icon":0},{"id":"2584490933","title":"Shandong Xinhua Pharmaceutical Gets China Marketing Nod for Reflux Esophagitis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2584490933","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584490933?lang=en_us&edition=fundamental","pubTime":"2025-11-18 18:04","pubTimestamp":1763460282,"startTime":"0","endTime":"0","summary":"Chinese drug regulators granted Shandong Xinhua Pharmaceutical (SHE:000756) marketing approval for its vonoprazan fumarate drug for reflux esophagitis, according to a Tuesday filing with the Shenzhen bourse.Reflux esophagitis is an inflammation of the esophagus due to stomach acid.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"1123855845","title":"Shandong Xinhua Pharmaceutical (000756.SZ) Gains Approval for Vonoprazan Fumarate API Marketing Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1123855845","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123855845?lang=en_us&edition=fundamental","pubTime":"2025-11-17 17:06","pubTimestamp":1763370396,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical Company Limited (000756.SZ) announced that it has received the Chemical Drug API Marketing Approval Notice for vonoprazan fumarate issued by the National Medical Products Administration. The drug is primarily indicated for the treatment of reflux esophagitis.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2584285643","title":"Shandong Xinhua Pharmaceutical Secures Regulatory Approval for Vonoprazan Fumarate API","url":"https://stock-news.laohu8.com/highlight/detail?id=2584285643","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584285643?lang=en_us&edition=fundamental","pubTime":"2025-11-17 16:53","pubTimestamp":1763369629,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical Company Limited has announced that it has received the Notification of Approval of Marketing Application for Chemical Active Pharmaceutical Ingredients from the National Medical Products Administration for its domestically produced Vonoprazan Fumarate. This regulatory approval is expected to further expand the company's product line and enhance its overall competitiveness. The company notes that the pharmaceutical sales business remains subject to changes in industry policies, procurement processes, and other market factors. No grant or funding from multiple organizations was mentioned in the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Xinhua Pharmaceutical Company Ltd. published","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL9lwLNt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2584643169","title":"Shandong Xinhua Pharmaceutical Co Ltd -  Approval for Chemical Active Pharmaceutical Ingredients","url":"https://stock-news.laohu8.com/highlight/detail?id=2584643169","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584643169?lang=en_us&edition=fundamental","pubTime":"2025-11-17 16:48","pubTimestamp":1763369326,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nFWN3WQ1O8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["000756","BK0164","BK0239"],"gpt_icon":0},{"id":"2584643137","title":"Shandong Xinhua Pharmaceutical -  Vonoprazan Fumarate Obtained Approval of Marketing Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2584643137","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584643137?lang=en_us&edition=fundamental","pubTime":"2025-11-17 16:48","pubTimestamp":1763369326,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nFWN3WQ1O8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["000756","BK0239","BK0164"],"gpt_icon":0},{"id":"2579560450","title":"Xinhua Pharmaceutical Gets Registration Certificate for Osteoporosis Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2579560450","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579560450?lang=en_us&edition=fundamental","pubTime":"2025-10-31 18:34","pubTimestamp":1761906883,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical  received a drug registration certificate for its alendronate sodium oral solution issued under the authority of China's National Medical Products Administration, a Friday Hong Kong bourse filing said.The drug is suitable for the treatment of osteoporosis in postmenopausal women toprevent hip and spinal fractures and in men to increase bone mass.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["00719","BK0239","BK1515","000756","BK1191","BK0164"],"gpt_icon":0},{"id":"1156550056","title":"Shandong Xinhua Pharmaceutical (000756.SZ) Obtains Drug Registration Certificate for Alendronate Sodium Oral Solution","url":"https://stock-news.laohu8.com/highlight/detail?id=1156550056","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156550056?lang=en_us&edition=fundamental","pubTime":"2025-10-31 16:46","pubTimestamp":1761900381,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical Company Limited (000756.SZ) announced that it has received the Drug Registration Certificate for Alendronate Sodium Oral Solution (hereinafter referred to as \"the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2579453529","title":"Shandong Xinhua Pharmaceutical Obtains Drug Registration Certificate for Alendronate Sodium Oral Solution","url":"https://stock-news.laohu8.com/highlight/detail?id=2579453529","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579453529?lang=en_us&edition=fundamental","pubTime":"2025-10-31 16:28","pubTimestamp":1761899306,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical Company Ltd. has announced that it has obtained a Drug Registration Certificate for its Alendronate Sodium Oral Solution. The regulatory approval follows the company's submission of application materials to the Center for Drug Evaluation of the National Medical Products Administration, with Shandong Langnuo Pharmaceutical Co., Ltd. involved in the technology development and transfer. Under a contract signed in May 2024, Xinhua Pharmaceutical has secured all rights and benefits to the product's registration approval documents and related intellectual property after fulfilling payment obligations to Shandong Langnuo. No grant or funding was mentioned as being obtained by multiple organizations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as finan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL7jD2ZK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0164","BK0239","000756"],"gpt_icon":0},{"id":"2579535134","title":"Shandong Xinhua Pharmaceutical - Received Drug Registration Certificate for Alendronate Sodium Oral Solution Issued by Nmpa China","url":"https://stock-news.laohu8.com/highlight/detail?id=2579535134","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579535134?lang=en_us&edition=fundamental","pubTime":"2025-10-31 16:26","pubTimestamp":1761899208,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nFWN3WC06B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","BK0164","000756"],"gpt_icon":0},{"id":"2578774660","title":"Shandong Xinhua Pharma Renews Trademark Licence with Hualu; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578774660","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578774660?lang=en_us&edition=fundamental","pubTime":"2025-10-27 11:19","pubTimestamp":1761535144,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical  said it has renewed its trademark licence agreement with Shandong Xinhua Pharmaceutical Branch of Hualu for another three years from January 2026 to December 2028, according to an Oct. 24 Hong Kong bourse filing.Hong Kong-listed shares of the firm were down over 3% in Monday morning trade.Under the new agreement, the company will pay an annual licence fee of about 14.4 million yuan, up from 10 million yuan under the previous arrangement.The agreement allows the company to continue using the \"Xinhua\" trademark for its pharmaceutical and chemical products in and outside mainland China, it said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK0164","000756","00719","BK1515","BK1191"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1997-08-06","address":"山东省淄博市张店区高新技术产业开发区化工区","stockEarnings":[{"period":"1week","weight":-0.0044},{"period":"1month","weight":0.0259},{"period":"3month","weight":0.0025},{"period":"6month","weight":0.07},{"period":"1year","weight":-0.0194},{"period":"ytd","weight":0.023}],"companyName":"山东新华制药股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"68977万元","compareEarnings":[{"period":"1week","weight":0.0128},{"period":"1month","weight":0.0215},{"period":"3month","weight":0.025},{"period":"6month","weight":0.1335},{"period":"1year","weight":0.1631},{"period":"ytd","weight":0.1687}],"survey":"　　山东新华制药股份有限公司的主营业务是开发、制造和销售化学原料药、制剂及化工产品。公司的主要产品是“新华牌”解热镇痛类药物、心脑血管类、抗感染类及中枢神经类等药物。1个项目获山东省2024年度科技进步二等奖。","serverTime":1766466363101,"listedPrice":3.45,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shandong Xinhua Pharmaceutical Company Limited(000756),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shandong Xinhua Pharmaceutical Company Limited(000756) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shandong Xinhua Pharmaceutical Company Limited,000756,Shandong Xinhua Pharmaceutical Company Limited股票,Shandong Xinhua Pharmaceutical Company Limited股票老虎,Shandong Xinhua Pharmaceutical Company Limited股票老虎国际,Shandong Xinhua Pharmaceutical Company Limited行情,Shandong Xinhua Pharmaceutical Company Limited股票行情,Shandong Xinhua Pharmaceutical Company Limited股价,Shandong Xinhua Pharmaceutical Company Limited股市,Shandong Xinhua Pharmaceutical Company Limited股票价格,Shandong Xinhua Pharmaceutical Company Limited股票交易,Shandong Xinhua Pharmaceutical Company Limited股票购买,Shandong Xinhua Pharmaceutical Company Limited股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shandong Xinhua Pharmaceutical Company Limited(000756),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shandong Xinhua Pharmaceutical Company Limited(000756) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction